Article
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations.
The Journal of clinical endocrinology and metabolism - 1 Dec 2007
Liu Dingxie, Liu Zhi, Jiang David, Dackiw Alan P, Xing Mingzhao
Abstract excerpt
CONTEXT: Targeting MAPK kinase (MEK) in the MAPK pathway is a potentially effective therapeutic strategy for thyroid cancer. OBJECTIVE: The objective of the study was to investigate genotype-dependent therapeutic potential of the MEK inhibitor CI-1040 for thyroid cancer. EXPERIMENTAL DESIGN: We examined the effects of CI-1040 on proliferation, apoptosis, transformation, thyroid gene reexpression, and xenograft...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.